You’re using a public version of DrugPatentWatch with 5 free searches available | Register to unlock more free searches. CREATE FREE ACCOUNT

Last Updated: March 19, 2024

LASTACAFT Drug Patent Profile


✉ Email this page to a colleague

« Back to Dashboard


Which patents cover Lastacaft, and when can generic versions of Lastacaft launch?

Lastacaft is a drug marketed by Abbvie and is included in one NDA. There are two patents protecting this drug and one Paragraph IV challenge.

This drug has forty-six patent family members in thirty countries.

The generic ingredient in LASTACAFT is alcaftadine. There are six drug master file entries for this compound. Two suppliers are listed for this compound. Additional details are available on the alcaftadine profile page.

DrugPatentWatch® Generic Entry Outlook for Lastacaft

Lastacaft was eligible for patent challenges on July 28, 2014.

There have been five patent litigation cases involving the patents protecting this drug, indicating strong interest in generic launch. Recent data indicate that 63% of patent challenges are decided in favor of the generic patent challenger and that 54% of successful patent challengers promptly launch generic drugs.

Indicators of Generic Entry

< Available with Subscription >

  Try a Trial

Drug patent expirations by year for LASTACAFT
Drug Prices for LASTACAFT

See drug prices for LASTACAFT

Recent Clinical Trials for LASTACAFT

Identify potential brand extensions & 505(b)(2) entrants

SponsorPhase
Allergan
ORA, Inc.Phase 4
Starx Research Center, LLCPhase 4

See all LASTACAFT clinical trials

Pharmacology for LASTACAFT
Anatomical Therapeutic Chemical (ATC) Classes for LASTACAFT
Paragraph IV (Patent) Challenges for LASTACAFT
Tradename Dosage Ingredient Strength NDA ANDAs Submitted Submissiondate
LASTACAFT Ophthalmic Solution alcaftadine 0.25% 022134 1 2014-07-30

US Patents and Regulatory Information for LASTACAFT

LASTACAFT is protected by two US patents.

Patents protecting LASTACAFT

Ophthalmic compositions containing alcaftadine
Patent Number: ⤷  Try a Trial
Patent Expiration: ⤷  Try a Trial
Patented Use: USE OF LASTACAFT TO TEMPORARY RELIEVE ITCHY EYES DUE TO POLLEN, RAGWEED, GRASS, ANIMAL HAIR AND DANDER

Ocular allergy treatments with alcaftadine
Patent Number: ⤷  Try a Trial
Patent Expiration: ⤷  Try a Trial
Patented Use: USE OF LASTACAFT TO TEMPORARY RELIEVE ITCHY EYES DUE TO POLLEN, RAGWEED, GRASS, ANIMAL HAIR AND DANDER

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Abbvie LASTACAFT alcaftadine SOLUTION/DROPS;OPHTHALMIC 022134-001 Jul 28, 2010 OTC Yes Yes ⤷  Try a Trial ⤷  Try a Trial ⤷  Try a Trial
Abbvie LASTACAFT alcaftadine SOLUTION/DROPS;OPHTHALMIC 022134-001 Jul 28, 2010 OTC Yes Yes ⤷  Try a Trial ⤷  Try a Trial Y ⤷  Try a Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

International Patents for LASTACAFT

When does loss-of-exclusivity occur for LASTACAFT?

Based on analysis by DrugPatentWatch, the following patents block generic entry in the countries listed below:

Argentina

Patent: 0278
Estimated Expiration: ⤷  Try a Trial

Patent: 1697
Estimated Expiration: ⤷  Try a Trial

Australia

Patent: 07234957
Estimated Expiration: ⤷  Try a Trial

Brazil

Patent: 0710085
Estimated Expiration: ⤷  Try a Trial

Canada

Patent: 48115
Estimated Expiration: ⤷  Try a Trial

Chile

Patent: 07000916
Estimated Expiration: ⤷  Try a Trial

China

Patent: 1460176
Estimated Expiration: ⤷  Try a Trial

Patent: 2895234
Estimated Expiration: ⤷  Try a Trial

Costa Rica

Patent: 414
Estimated Expiration: ⤷  Try a Trial

Denmark

Patent: 04196
Estimated Expiration: ⤷  Try a Trial

Patent: 50209
Estimated Expiration: ⤷  Try a Trial

Ecuador

Patent: 088786
Estimated Expiration: ⤷  Try a Trial

Eurasian Patent Organization

Patent: 6221
Estimated Expiration: ⤷  Try a Trial

Patent: 0870396
Estimated Expiration: ⤷  Try a Trial

European Patent Office

Patent: 04196
Estimated Expiration: ⤷  Try a Trial

Patent: 50209
Estimated Expiration: ⤷  Try a Trial

Hong Kong

Patent: 31331
Estimated Expiration: ⤷  Try a Trial

Israel

Patent: 4473
Estimated Expiration: ⤷  Try a Trial

Japan

Patent: 92277
Estimated Expiration: ⤷  Try a Trial

Patent: 39716
Estimated Expiration: ⤷  Try a Trial

Patent: 09533333
Estimated Expiration: ⤷  Try a Trial

Patent: 13144703
Estimated Expiration: ⤷  Try a Trial

Patent: 15131820
Estimated Expiration: ⤷  Try a Trial

Jordan

Patent: 58
Estimated Expiration: ⤷  Try a Trial

Malaysia

Patent: 3669
Estimated Expiration: ⤷  Try a Trial

Mexico

Patent: 08012657
Estimated Expiration: ⤷  Try a Trial

New Zealand

Patent: 1690
Estimated Expiration: ⤷  Try a Trial

Nicaragua

Patent: 0800261
Estimated Expiration: ⤷  Try a Trial

Norway

Patent: 1147
Estimated Expiration: ⤷  Try a Trial

Patent: 084593
Estimated Expiration: ⤷  Try a Trial

Peru

Patent: 080053
Estimated Expiration: ⤷  Try a Trial

Poland

Patent: 04196
Estimated Expiration: ⤷  Try a Trial

Patent: 50209
Estimated Expiration: ⤷  Try a Trial

Singapore

Patent: 0044
Estimated Expiration: ⤷  Try a Trial

South Africa

Patent: 0809327
Estimated Expiration: ⤷  Try a Trial

South Korea

Patent: 1321731
Estimated Expiration: ⤷  Try a Trial

Patent: 080110881
Estimated Expiration: ⤷  Try a Trial

Spain

Patent: 94655
Estimated Expiration: ⤷  Try a Trial

Patent: 52823
Estimated Expiration: ⤷  Try a Trial

Taiwan

Patent: 50721
Estimated Expiration: ⤷  Try a Trial

Patent: 78990
Estimated Expiration: ⤷  Try a Trial

Patent: 0815016
Estimated Expiration: ⤷  Try a Trial

Patent: 1446249
Estimated Expiration: ⤷  Try a Trial

Ukraine

Patent: 938
Estimated Expiration: ⤷  Try a Trial

Uruguay

Patent: 254
Estimated Expiration: ⤷  Try a Trial

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

See the table below for additional patents covering LASTACAFT around the world.

Country Patent Number Title Estimated Expiration
China 1070368 ⤷  Try a Trial
Poland 170776 ⤷  Try a Trial
Slovenia 9200105 IMIDAZO(2,1-B)(3)BENZAZEPINE DERIVATIVES, COMPOSITIONS AND METHOD OF USE ⤷  Try a Trial
Zambia 2992 Imidazo (2,1-b) (3) benzazepine derivatives compositions and method of use ⤷  Try a Trial
Norway 341147 ⤷  Try a Trial
Morocco 22553 ⤷  Try a Trial
Jordan 3358 معالجات حساسية العيون (Ocular Allergy Treatments) ⤷  Try a Trial
>Country >Patent Number >Title >Estimated Expiration

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.